Clinical trials: Lung Cancer Non Small Cell, open to volunteers
Non Small Cell Lung Cancer, Lung Cancer
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC).
- Trial name
- NCT05401110
- Testing
- Osimertinib, Carotuximab
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Karen Reckamp, MD, MS
Non-Small-Cell Lung
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
- Trial name
- MAP (NCT07316062)
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI
Cancer radiation treatment plans that employ lung functional avoidance methods require 3D maps that differentiate regions of healthy lung function from regions of functional compromised tissue to deliver sufficient dose to the…
- Trial name
- GuidedRT (NCT07355231)
- Testing
- Hyperpolarized xenon MRI
- Volunteers
- 10 people
- Sponsor
- Xemed LLC
Advanced Non-Small Cell Lung Cancer
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
This is an open-label, multicenter, randomized phase 2 trial for patients with tyrosine kinase inhibitor-naïve ALKrearranged advanced NSCLC. Subjects are initially treated with lorlatinib for 12 weeks.
- Trial name
- NCT07415005
- Testing
- Lorlatinib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Robotics, Lung Cancer
SP Robotic Versus VATS Anatomical Pulmonary Resection for Patients With NSCLC
Single-POrt Robotic-assisted thoracic surgery versus single-port video-assisted Thoracic Surgery major pulmonary resection for patients with non-small cell lung cancer (SPORTS trial): a single-center, a single blinded, randomized…
- Trial name
- SPORTS (NCT06202690)
- Testing
- Single-port robotic-assisted thoracic surgery, Single-port video-assisted thoracoscopic surgery
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
NSCLC, TNBC
A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer
This is a single-arm, multicenter, open-label Phase II clinical study evaluating the efficacy and safety of IMM2510 in combination with chemotherapy as first-line treatment in patients with stage IV metastatic or recurrent NSCLC…
- Trial name
- NCT06746870
- Testing
- IMM2510, Chemotherapy (pemetrexed + cisplatin/carboplatin), Chemotherapy (paclitaxel + cisplatin/carboplatin)
- Volunteers
- 148 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Non-Small-Cell Lung Cancer
Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure
Efficacy and Safety of Vebreltinib in Combination With PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFR Mutations, MET Amplification and/or Overexpression, Locally Advanced or Metastatic Non-Small Cell…
- Trial name
- KYLIN-3 (NCT06970782)
- Testing
- Vebreltinib, PLB1004, Pemetrexed plus Carboplatin or Cisplatin
- Volunteers
- 278 people
- Sponsor
- Avistone Biotechnology Co., Ltd.
Lung Cancer Stage III
Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies.
- Trial name
- MRD-LUNG (NCT06111807)
- Testing
- ctDNA
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 248 people
- Sponsor
- University Medical Center Groningen
Non-Small Cell Lung Cancer, Hyperlipidemia
LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer
The goal of this observational study is to learn about the long-term effects of Lorlatinib related hyperlipidemia in NSCLC patients who take Lorlatinib for at least 21 days.
- Trial name
- NCT06876675
- Testing
- Lorlatinib
- Where
- China
- Volunteers
- 167 people
- Sponsor
- Peking University Third Hospital
Lung Neoplasms, Lung Cancer, Nonsmall Cell
A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery
This study aims to verify the efficacy and safety of osimertinib in patients with EGFR-sensitive mutation non-small cell lung cancer who progressed after adjuvant targeted therapy following radical surgery.
- Trial name
- NCT06530719
- Testing
- Osimertinib mesylate
- Volunteers
- 54 people
- Sponsor
- Jin Ying
Lung Cancer (Non-Small Cell)
A Phase II Study of SKB571 in Patients With Lung Cancer
This is a multicenter, phase II study. The purpose of this study is to evaluate the safety and preliminary anti-tumor activity of SKB571 in patients with advanced non-small cell lung cancer.
- Trial name
- NCT07230405
- Testing
- SKB571 for injection
- Where
- 2 sites in China
- Volunteers
- 295 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
EGFR mutation positive advanced NSCLC patients with uncleared ctDNA have poor prognosis, whether they can benefit from combination therapy has not been reported.
- Trial name
- FOCUS-C (NCT05334277)
- Testing
- Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
- Where
- 26 sites in China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Stage II Lung Cancer, Lung Cancer
Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study
The purpose of this study is to test the feasibility of the Precise Exercise Regimen for Cancer Care (PERCC) exercise program in participants with stage II-III primary lung cancer.
- Conditions
- Stage II Lung Cancer, Lung Cancer, Non-small Cell Lung Cancer, NSCLC
- Trial name
- PERCC (NCT07412041)
- Testing
- PERCC
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Non Small Cell Lung Cancer, Healthy
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients.
- Trial name
- PROPHETIC (NCT05736029)
- Testing
- blood, stool and tissue samples collection
- Where
- United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- OncoHost Ltd.
NSCLC, Advanced Solid Tumor
YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)
This is an open-label, dose-escalation and cohort expansion study to evaluate the safety and preliminary efficacy of YSCH-01 in subjects with pulmonary metastasis of advanced solid tumors and advanced non-small cell lung cancer…
- Trial name
- NCT07793500
- Testing
- YSCH-01
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
To evaluate the efficacy and safety of glumetinib combined with osimertinib as the first-line treatment for locally advanced or metastatic NSCLC.
- Trial name
- NCT06908772
- Testing
- Glumetinib Tablets, Osimertinib Mesylate Tablets
- Volunteers
- 390 people
- Sponsor
- Shanghai JMT-Bio Inc.
Non-small Cell Lung Cancer
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2)…
- Trial name
- NCT04297605
- Testing
- Pembrolizumab, Pemetrexed (Chemotherapy), Nab-paclitaxel (Chemotherapy)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Rochester
Lung Cancer, Lung Diseases
Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer
This study aims to explore the efficacy of Trop2, EpCAM-specific PET/CT imaging for noninvasive visualization of Trop2 or EpCAM expression levels in non-small cell lung cancer; and to explore the differences between novel…
- Conditions
- Lung Cancer, Lung Diseases, Lung Neoplasms, Lung Cancer Metastatic
- Trial name
- NCT07026110
- Testing
- [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
Non-Small Cell Lung Cancer, Advanced/Metastatic
Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
This is a two-part, biomarker-guided Phase 1/2 study evaluating the safety, feasibility, and preliminary anti-tumor activity of off-the-shelf dual-target CAR-NK cells in participants with advanced or metastatic NSCLC whose tumors…
- Trial name
- DUO-NK-NSCLC (NCT07641023)
- Testing
- Dual-target CAR-NK cells, Lymphodepleting chemotherapy, Supportive care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.